In short
A weekend Bloomberg Businessweek episode covering (1) Alan Greenspan’s legacy and how Fed communication/mandate focus may shift under Kevin Warsh, (2) whether the Fed can still hit 2% inflation amid productivity-driven labor dynamics and AI, (3) the “peptide gold rush” fueling an unregulated black market in injectable peptides.
Guests/backgrounds
Jim Caron, Chief Investment Officer at Morgan Stanley Investment Management (Portfolio Solutions), former Fed-era market perspective since early 1990s. Amanda Moll, Bloomberg Businessweek senior reporter; Madison Muller, Bloomberg News U.S. healthcare reporter.
Key claims
Greenspan-era transparency changed markets; Warsh would narrow the Fed’s remit and reduce “telegraphing,” possibly shifting inflation inputs and models. Productivity (including AI) could lower unemployment without necessarily raising inflation; AI may boost demand and create winners/losers via operating leverage. Black market peptides are often imported vial powders, reconstituted and injected without FDA-approved safety/efficacy oversight.
Notable examples
Greenspan vs Volcker communication timing; unemployment falling (e.g., 4.3 to 3.8) without inflationary pressure; Jevons paradox for AI; peptide supply chain nodes like a Prague lab (Peter “Magic”) and FDA July committee review.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOReflection on Alan Greenspan
0:30 to 0:49
Reflecting on the legacy of Alan Greenspan after his passing.
“Small businesses are the pulse of every community.”
Reflection on Alan Greenspan
0:53 to 2:00
Reflecting on the legacy of Alan Greenspan after his passing.
“The Chase mobile app is available for select mobile devices.”
Market Overview and Tensions
2:00 to 2:59
Discussing global market trends amidst geopolitical tensions.
“Welcome to the weekend edition of Bloomberg Business Week.”
Interview with Jim Caron
2:59 to 4:47
A deep dive into the legacy of Alan Greenspan with Jim Caron.
“All of that to come, we do begin with a comprehensive market and macroeconomic check-in.”
Monetary Policy and Its Evolution
4:47 to 8:21
Examining how monetary policy has evolved since Greenspan.
“Like, there's pre-Greenspan and then there's post-Greenspan, right?”
Current Economic Challenges
8:21 to 13:32
Discussing current challenges and shifts in economic data interpretation.
“I mean, he opened it up more transparency.”
Introduction to Jim Caron
14:00 to 14:16
Jim Caron discusses challenges in interpreting job data.
“if weekly jobless claims were a bit better.”
Introduction to Jim Caron
14:54 to 15:27
Jim Caron discusses challenges in interpreting job data.
“So there's a lot of noise about AI, but time's too tight for more promises.”
Resuming Discussion on Inflation Targets
16:45 to 17:08
The conversation returns to inflation targets and the Fed's strategies.
“Welcome back to the weekend edition of Bloomberg Business Week.”
The Impact of AI on Productivity and Jobs
17:08 to 19:20
Caron discusses AI's potential effects on productivity and employment.
“In the 90s, we didn't really get to 2 % as a target either.”
Show all 26 chapters
Adapting to AI in the Workforce
19:20 to 22:26
Exploring how workers must adapt to the rise of AI technologies.
“So when we think about AI, people think about it in terms of profit margins.”
Investment Insights on AI and Space
22:26 to 24:27
Caron shares insights on AI's role in investment and space industries.
“Like learning how to ask the right question.”
Economic Implications of Current Events
24:27 to 28:00
Discussion focuses on the economic impact of geopolitical events.
“and their productivity is off the charts.”
Market Impact of Iran's Oil Strategy
28:00 to 28:54
Discussion on how Iran's actions impact global oil prices and market perceptions.
“And I also think, though, that what Iran also knew is that the world and, you know, China's a big consumer of oil, for example, would have some patience up to a certain point.”
The Underground Economy of Peptides
28:54 to 30:15
Introduction to the booming market for peptides and their various claims.
“More of our conversation with Jim Caron we got into positioning when it comes to global equities.”
The Underground Economy of Peptides
30:20 to 31:28
Introduction to the booming market for peptides and their various claims.
“Brokered services by Open to the Public Investing, Inc., Member FINRA, and SIPC.”
Exploring the Peptide Gold Rush
32:13 to 33:05
Discussion on the rise of peptides and their risks, featuring Amanda Mull.
“This is Bloomberg Business Week Daily with Carol Masser and Tim Stenevek on Bloomberg Radio.”
Understanding Black Market Peptides
33:05 to 34:27
Insights into what black market peptides are and how they are used.
“One of the things is that most people actually don't know what they are, don't know how to explain them, even if they think that they do.”
The Efficacy and Risks of Peptides
34:27 to 36:04
Discussion on the effectiveness and safety concerns around black market peptides.
“One thing that may inform the question is Carol's not on Instagram.”
Regulatory Challenges for Peptides
36:04 to 37:55
Exploring the regulatory landscape and challenges of black market peptides.
“And so it's hard to know whether the effects that they're experiencing, the anti-inflammatory effects, the weight loss, all of the things are because of Lily's drug, which we know does work.”
Peter Magic and the Peptide Trade
37:55 to 39:46
Introduction to Peter Magic, a key player in the peptide black market.
“So the existence of these peptide supply chains, like outside of regulatory control, is like very enticing to the whole like Maha mindset, I would say.”
Safety Practices in Peptide Use
39:46 to 41:11
Discussion on the safety practices and risks associated with peptide injections.
“like sort of a foothold through some of the same users like fitness, hobbyists, biohackers, people who are interested in perfecting their own form.”
Future of Peptide Approval in Healthcare
41:11 to 42:00
Speculation on the future of peptide drugs and potential FDA approval processes.
“Well, we, there are some doctors who are also fans of them.”
FDA's Approval Challenges for Sunscreen Filters
42:00 to 43:38
Learn about the complexities the FDA faces in approving new sunscreen filters and the implications for competition.
“years since we had gotten a new sunscreen filter approved, even though there's lots of effective ones being used in Europe and Asia for decades.”
Expert Insights on Sunscreen Safety
43:38 to 44:00
Hear expert opinions regarding the safety and evidence around sunscreen filters ahead of the FDA meeting.
“Well, I think many of their proponents agree that there's not any data, but they think that they should be able to give it a shot if they want to.”
Expert Insights on Sunscreen Safety
45:03 to 45:33
Hear expert opinions regarding the safety and evidence around sunscreen filters ahead of the FDA meeting.
“For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges.”
Transcript
Automatic transcript. May contain errors.0:00What if data didn't sit still? What if intelligence moved with us? Not buried in reports, but activated in real time, where lives are being shaped, where decisions are being made. It all starts with a question. Where is the potential? Cotality turns data into clarity, intelligence into insight, insight into action. Because when intelligence moves, we all move forward. Cotality. Intelligence beyond bounds. Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. Chase for Business helps business owners like you with personalized guidance and convenient digital tools all in one place.
0:42With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for Business. Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank, N.A., member FDIC. Copyright 2026, JPMorgan Chase and Company. The thing about AI for business, it may not automatically fit the way your business works. At IBM, we've seen this firsthand. But by embedding AI across HR, IT, and procurement processes, we've reduced costs by millions, slash repetitive tasks, and freed thousands of hours for strategic work.
1:27Now we're helping companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business, IBM. This is Bloomberg Business Week Daily, reporting from the magazine that helps global leaders stay ahead. With insight on the people, companies, and trends shaping today's complex economy. Plus, global business, finance, and tech news as it happens. Bloomberg Business Week Daily with Carol Masser and Tim Stenevek on Bloomberg Radio. Hi, everyone. Welcome to the weekend edition of Bloomberg Business Week. This past week, the financial world marked the loss of Federal Reserve Chairman Alan Greenspan, who passed away at the age of 100, prompting a deep reflection on his immense economic legacy and decades of market influence.
2:17His passing happened at the start of what turned out to be a volatile week for global markets. Meantime, geopolitical tension is still top of mind. As fast-moving, ever-changing U.S.-Iran negotiations aimed at cementing a final peace deal to end the war take shape. For all the important details on these developing stories, head on over to Bloomberg.com and always check out the Bloomberg Terminal. With that in mind, this hour we bring a deep look at the macro market backdrop, AI, monetary policy via the Fed, and also the legacy of the late former Fed chair, Alan Greenspan. Plus the latest global phenomenon that's driving billions of dollars into unregulated markets.
2:52From Silicon Valley and online fitness communities, the obsession with peptides has triggered a black market boon. More on that a little later. It's a great Businessweek story. All of that to come, we do begin with a comprehensive market and macroeconomic check-in. For that, we leaned on Jim Caron, who is Chief Investment Officer of Portfolio Solutions at Morgan Stanley Investment Management. We covered a lot with Jim, but of course, Carol, we had to start on the life and legacy of Alan Greenspan. He was a legend. So I, you know, if we put this in perspective, and I think it's very important to have context around this, he started his position as chair in 1987.
3:28He ended in 2006. That's a 19 year period. So for most people, that's a large chunk of their career. I started in the business in 91, 92. That's all I knew for 14 or 15 years of the starting point of my career. He was somebody that was not going to be challenged easily by other members of the Fed. It's whatever he said went, and that was it. But he also did a bunch of different things. He changed things at the Fed in the sense that he made it a lot more transparent, if I could say those words. So the way the Fed operated, And we take this for granted today that you find out on Wednesday at 2 o 'clock what the Fed's decision was, and we all go to work.
4:13Prior to Greenspan, it was Volcker. And what happened at about 4.15, 4.10 on a Thursday afternoon, you got money supply data. Based on what the money supply data was, that was the change in policy. You had to figure it out. Nobody told you if it was 25 or 50 basis points. You were guessing. And you were trying to analyze and figure out what that was. So what Greenspan started to introduce through communications and things like that was what today we take for granted was absolutely monumental and groundbreaking as far as saying, hey, by the way, we just hiked or cut 25 basis points and that's all it is.
4:52Is it too much, though? Like, would some say it's gone too far? So there's been iterations. Like, there's pre-Greenspan and then there's post-Greenspan, right? So what happened in the 19 years subsequent, from 2006, say, to 2026, what we've had now is Bernanke, Yellen, and Powell. They've all followed effectively the Greenspan mode, but they added on to it. Now, clearly, Bernanke had a very special situation in the financial crisis. He had to do enhanced communications and things of that nature. I think that what is it too much today in terms of communication? I'm going to say that it is a bit because what the Fed is trying to do is they're trying to telegraph and televise too much such that they're actually directing and dictating how the markets should think about things, as opposed to what Warsh said, which is let the markets figure it out.
5:52I mean, so the way I think about Kevin Warsh— So we're being managed? Well, I mean, you know, the way I think about Kevin Warsh, if I'm going to put him in this period of time from 1987 to 2026, I'm going to say that what Warsh is trying to do is bring us back to the period that was pre-Ben Bernanke. So it was Greenspan in the 1990s. So very similar economic setup, too. Big CapEx cycle. Big productivity boom, you know, that we're going through. And I think what Warsh is trying to do is bring us back to that period where he lets the markets assess what monetary policy ought to be, as opposed to what Greenspan did.
6:29Greenspan was the guy that really started to come in, because Volcker and everybody else just looked at money supply, M1, M2. They were, you know, very, very much, that's what they did. Greenspan was the one who started saying, you know, we should think about GDP growth and the labor market and inflation. And let's talk about inflation anchoring and all of these various things. Things that we think of today is very common. It was very uncommon at the time. So I'd say let's give Kevin Warsh an opportunity. This is his moment in history. He wants to remake the Fed, but this isn't groundbreaking what I think Warsh is trying to do.
7:01I think he's just getting back to a period that looks more like the 1990s. So it's fair to say you see a hint or more of Alan Greenspan in Kevin Warsh today. Yeah, I do. Now, whenever you compare somebody to somebody who was a legend and somebody just starting out, that's always a very, very difficult. We'll see how Warsh does. It's going to be a long journey and a long road ahead. But I think on paper, conceptually, what Kevin Warsh is trying to do is get the Fed back to a much more narrow focus. Not as narrow as the Volcker Fed, which was just money supply. But something that's a little more growth, inflation outlook, jobs market, but let's ease up on the communications.
7:48I think he's really just going back to a 1990s Greenspan model right now. And that's my perspective. And a lot of people weren't even around in the 90s in this business practicing, right? So they don't really have a good perspective on this. It wasn't chaos. It was fine. You know, you just have to get used to the new, there's a new sheriff in town. What's the downside of kind of where we are and what we expect from today's Fed? I think the downside is that there's a lot of mission creep with the Fed, right? So now we have to put this in context as well. Prior to the financial crisis, we had this much more narrow remit.
8:22This is what Greenspan kind of created. I mean, he opened it up more transparency. Then Bernanke kicked the door wide open. He had to. We had a financial crisis. We had interest policy. We had QE. We had policy rates at zero. So we had to find a way to communicate policy to the markets. I totally get it. But what happens is that once the Fed starts to have this mission creep and they start to be asked to do more and more, even from a regulatory standpoint, or even the Fed was being asked, what's your policy on climate, things like that, this is not what the Fed's job is. The Fed, and according to Kevin Warsh, should color in a very, very narrow set of lines and stick to what their job is.
9:02Under Volcker, it was money supply. But what if the economy has gotten more complicated? Climate change is an issue. Companies have to think about it, you know, because it is ultimately going to impact their bottom line. But does it affect the dual mandate, I guess some might say? Well, it might because people can't work. You can extrapolate, right? So what Warsh is basically saying is, don't ask me that question. That is an elected official's job to do. My job is Kevin Warsh, right? if you're Kevin Warsh, if you're the chair of the Fed, is to, is price stability and full employment and to really focus on the price stability component.
9:39But don't you sometimes need, okay, I'm going to get into trouble, by needing a figure that's not political. But we understand that politics has certainly crept its way, Jim, into the U.S. Central Bank. But I think there are times we look at the Fed share, even if there is a political backdrop, as being kind of a voice of reason on all of these major issues that will impact economic growth globally, will impact corporate bottom lines. Like, is it not important to have that voice of reason? It is absolutely important to have a voice of reason. But in a position like that, in the way that I believe that Warsh interprets it, is that it's a very narrow remit.
10:18And one of the things that he said is that the Fed should have absolute independence on a narrow set of items. Everything else, this is not, this is what the Fed is, and this is not what the Fed does. And I think keeping that very, very clear and setting these boundaries, right? You know, we all have to set boundaries, right? You know, this is a very important aspect of things. Is like, look, don't ask me these questions. I mean, these aren't questions that are for Kevin Warsh, right? You know, so that's what he's basically saying. And what he says ultimately is that the Fed can do its job better if it's just doing the job that it was tasked to do, but is not being asked to solve all these other problems.
10:55In the words of Jay Powell, we'll stick to our knitting is what he said over and over again. So it just reminds me of, of that sort of go-to for him. So, so what does all this mean for, for rates under a Warsh regime? So there's a pretty clear, yeah, it was in the market in a very clear way. Well, yeah. So, so I, I have a, I have a very out of consensus view on this. Okay. Okay. So I, I actually think Warsh was more dovish than what the markets thought. Okay. So I, I know what he said in, in a traditional interpretation. So markets got it wrong. I think so. Okay. So, so effectively under a Bernanke, a Yellen and a Powell, if that's your mindset and say, look, traditionally, if I think about what war said, and I use that framework, Bernanke, Yellen and Powell, then yes, he was absolutely very hawkish, right?
11:44You know, So there's no question. But I think if you read between the lines and listen to what he's really saying, what he's saying is that he's going to create these task forces in terms of like, so how do we think about the data? So if you were to ask me a week ago, two weeks ago, what is the Fed's most favored measure of inflation? I'd say core PCE. That's the Fed's favored measure of inflation. Today, I don't know what it is. I don't know what the task force is going to say that it is. Is it year over year PCE? Or is it month over month? or is it three months over? This is what the task force is going to figure out.
12:16So the market, I think, for the next six months until this task force gets this all done, is going to be very confused as to what the inputs are to the Fed's large-scale policy model, which is what they call the FERBUS model, Federal Reserve Bank of the U.S. model. And what Warsh is doing is he's not saying I'm going to change the model. What he's saying is I want to look at different inputs. I want to think about productivity differently. Kevin Warsh is a supply side economist, he's going to start to create a lot of supply side indicators to inform him as opposed to the more traditional demand side components of the economy and those indicators.
12:58This is in my career, and I've been doing this since, you know, 91 92. So about 34 years is the most monumental shift that I've seen take place. I inherited Greenspan. When I started, Greenspan was there. That's all I knew. This is a major shift. And I think that people are underestimating how monumental of a shift this is and where they're going to get it wrong is by applying what they've learned over the last 25, 30 years under a Greenspan to then say, oh, well, this is how I would interpret this. I think the rules are, the ground is shifting. Not the rules of change, but the ground is shifting.
13:33So good that it's shifting? Good that we kind of take a look at a system that we've been kind of moving along for a long time. Well, I mean, you know, changes happen, right? So Greenspan changed it, right, when he came in because he felt, and you mentioned yourself, the economy has changed, right? So when we look at labor data and labor statistics, I think the data has been challenged for the last five years. The non-farm payroll data, for me, used to be the sun rose and set on the non-farm payroll data for most of my career. Last five years, not very informative. if weekly jobless claims were a bit better.
14:06So I think there's a lot of challenge to the data. That was Jim Caron, Chief Investment Officer of Portfolio Solutions at Morgan Stanley Investment Management. Coming up, we continue with Jim Caron. We zero in on the Fed's inflation battle and whether that elusive 2 % target is still realistic. You're listening to Bloomberg Business Week. This is Bloomberg.
14:27What if data didn't sit still? What if intelligence moved with us? not buried in reports, but activated in real time, where lives are being shaped, where decisions are being made. It all starts with a question. Where is the potential? Cotality turns data into clarity, intelligence into insight, insight into action. Because when intelligence moves, we all move forward. Cotality, intelligence beyond bounds. So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need.
15:08Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions. Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off. Deep in the work that moves the business. Let's create smarter business. IBM. Support for this show comes from Public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English.
15:46Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve of the workflow and your agent handles the risk. Monitoring the market, watching for your conditions, and executing your strategies exactly as defined. An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., member FINRA and SIPC.
16:29Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. This is Bloomberg Business Week Daily with Carol Masser and Tim Stenevek on Bloomberg Radio. Welcome back to the weekend edition of Bloomberg Business Week. We continue our conversation with Jim Caron. He's chief investment officer of Portfolio Solutions over at Morgan Stanley Investment Management. We kicked off this part of our discussion by zeroing in on the central bank's inflation mandate, specifically whether that elusive 2 % inflation target is still achievable in this economic climate or if the Fed is chasing a moving target.
17:08Here's Jim Caron. In the 90s, we didn't really get to 2 % as a target either. We didn't even really have the target of 2 % at that time, which is another thing. So maybe, as I'm saying, as Kevin Warsh is kind of going back to the 90s, maybe we should think about the target. Is it more of a range or is it a specific point target? And the other thing that I think is going to be very, very different is that the way that the traditional way over the last 25 years or so that we thought about controlling inflation was to adjust the jobs market, right? So if inflation is running too hot. This is the irrational exuberance.
17:45How do you control inflation? You kill the jobs market, you create a recession, you get the unemployment rate up, you get prices back down, and you tamp down inflation. What Warsh is saying is that if you're in this period of higher productivity, then lower levels of unemployment, so an unemployment rate that, say, falls from 4.3 to 3.8 or something like that, doesn't necessarily mean that it's going to be inflationary if it's because you're getting higher productive growth. That's a very supply side view of the world. And basically saying that if industry is creating more efficiencies, that doesn't necessarily create a higher inflation rate.
18:25So a lot is changing. And, you know, it's a lot of people should really just, you know, when they speak to say, look, I'm not really sure, but what I think is as opposed to being so definitive. So I'm keeping a very open mind about all of this. Does AI completely change everything that we're talking about? Possibly. Possibly. You know, I mean, I think the issues with AI that I have in economic forecasting is that it's kind of just going to look at the survey data. It's going to look at the available data sets that are out there, unless you train it to look at specific things. I just mean from productivity perspective.
19:01Oh, yeah. That's what I mean. A hundred percent. Yeah, yeah. I see what you're saying. Yeah, not on the data analysis, but just on productivity and what it does to this economy. So in my view, it does. Right. So I think the productivity, I think you're going to get a lot. I think you can get higher levels of growth and lower levels of unemployment. But if it's more productive because AI is becoming more efficient, it's going to be a positive. So when we think about AI, people think about it in terms of profit margins. Right. And today, the way they think about it is it reduces costs. So more AI, less junior analysts, higher unemployment rate.
19:37And that's kind of the negative view of AI. I don't think it's going to work that way. I think what we're going to see is you're going to have more AI. It's going to create more demand. It's the Jevon's paradox, right? Where when something becomes cheaper, you demand more of it, which is what I think AI is going to do. You'd have more people asking critical questions of this tool called AI. and we're going to be judging the results of these things. And ultimately, if you get better, more efficient decisions and higher productivity, these are the companies that actually use this. These are the winners.
20:12There's a lot of creative destruction here. There are going to be winners and losers. Yeah, I agree. Do you think that that means that some of the companies we talk about nonstop could be a possible loser down the road? Yeah, absolutely. Right? So it's all about adapting. And it's looking at companies that can actually use this tool very efficiently. So right now, there's a big productivity gap between the way that we evaluate this. We're just in the infancy of all this stuff, right? So if you ask any individual person, hey, do you use AI? Yes, I do. Are you more productive because you use it?
20:45Yes, I am. Okay, now go ask the CEO of that company. If your employee is 30 % more productive, are your profits 30 % higher? And they're going to say, I don't think so. Not yet. Over time, that gap, that productivity gap is going to narrow relative to the individual being more productive and the company becoming more productive. Companies right now don't quite know how to use this tool efficiently or effectively. But I think the concern that a lot of people have is that, well, maybe when an employee leaves, that employee doesn't need to be replaced by headcount. and and it's the margins that where you'll see and fewer people producing the same amount of work great for shareholders not so great for those folks with jobs yeah it could be right so so my take on it is that the real the real power of a powerful user of ai is somebody who can ask really good, creative, insightful questions.
21:51So the work that, you know, whether it's software, programmers, engineers that create a lot of the software, a lot of that work is going to get displaced, I think. But the people asking the questions, the more creative questions that come in that try to solve problems, I think that doesn't go away. And then you have to judge it, you have to interpret it, and then you have to apply it. And I think that's where the job growth is actually going to be. So maybe that liberal arts education. 100%. Hey, 100%. Talking to a Bowdoin guy here and a Colby guy here. So we're getting along right now. Yes, exactly.
22:26A barter girl here. But I think about that a lot. Like learning how to ask the right question. And we keep talking about this too. It's not these basic, simple questions. It's really complicated, smart, thoughtful questions. The critical thinking that you develop when you're writing those papers late at night That now AI is writing for you, unfortunately. So the kids aren't learning how to do it. Well, think about it. I mean, like, you know, you may not be able to code, but you can ask a lot of really good questions. Right. So there you go. I mean, and if you can ask really good questions, well, don't worry about it.
22:56The machine's going to code for you. Exactly. If you have a vision for something. Right. Because you have an analytical mind. Right. You have an idea for creating something. You no longer need to find that person to code for you. You can get Claude Code or Codex from OpenAI to do it for you. So Albert Einstein said that the true measure of intelligence is imagination. It's not all these hard technicals. It's as if you're very imaginative. That's actual intelligence. I'll go with Albert Einstein on this one. Yeah. It makes us think, you know, there are people who have been writing things about, you know, you have to give your mind, your brain kind of a moment to think, right?
23:30Some space to think rather than kind of nonstop, either on a computer or on your phone and thinking things through. when it comes to the spend that we see nonstop. And we've been talking a lot about SpaceX now tapping the debt market. I don't know. How do you work that into the investment narrative? Is it smart? Do we get nervous? Well, I mean, things are going to go in cycles. There's no question about this. So there is a large spend right now. And everybody's going to ask the question, is the juice worth the squeeze, right? We're spending a lot of money. Are we going to get the profits? Or is this going to happen?
24:06I think it will. It's going to happen over time, but it has to be an enterprise solution, meaning that companies, corporate America, is who's going to build data centers in space, for example. It's going to be the need from business that says, hey, I've got a whole team of people that I just hired, and they're using this AI engine, this AI tool, creating agents nonstop, and their productivity is off the charts. We need to do more of this. it's an enterprise solution that's going to actually create the profitability. And, and I don't think we're, I don't think we're close to it yet because right now you're asking CEOs like, Oh, so is this profitable?
24:46Like, yeah, I think it is. I mean, they're not quite sure how to measure it. Well, the flip side of that is some, some CFOs pulling back on, on those tokens because they're not necessarily seeing the ROI. Uber, for example, expensive. Yeah. Yeah. Yeah. It's a cost, it's a cost component, but like anything else, you know, tokenization is, is going to get commoditized. It's going to become cheaper. Um, do you remember like, Oh, don't print in color, right? You can't print in color because of ink was more, nobody really says that anymore. Right. You know? So I think it's one of these things that it's like, you know, I think it's going to get cheaper.
25:20What did I tell you, Carol, when I started working here six years ago, I was like, I like working here cause they don't count how many pages you print in color as opposed to where I used to work. And they're like, do not print in color or do not print at all. Yeah, exactly. Just read off of it. You know, it's funny when we talk and I feel like, I mean, we don't know what the timeframe is here, do we? We really don't. We're taking it day by day, week by week, month by month in terms of just kind of watching how this, you know, evolves. But what I do find interesting, and you mentioned ROI, like our conversations have evolved a lot more to talk about that when we're talking about artificial intelligence.
Read the full transcript
25:55We weren't doing that necessarily a year and a half ago. Yeah. So, so I think if you look at any business cycle, right, you've got the early adopters, you've got the late adopters, right? It's never a straight line. It's never like you're early. Then all of a sudden you kind of get there. It's like, it's always exponential. So you start off, there are going to be some early adopters. The way that the market's going to identify that is these are the companies who are going to get rewarded. So Jim, just early adopters, early adopters. Well, I think it's fair to say some of those are getting rewarded right now.
26:26But apart from those companies, the front, the developers of the frontier models, the hyperscalers, who else could be winners? Where else could you find winners? I think you're going to find it all across the spectrum. You know, it's not a question of specific industries. It's really a question of which companies in which sectors are adopting these tools and unlocking operating leverage. That's going to happen in healthcare. That's going to happen in an industry. That's going to happen in software and technology. It's going to happen all across the financial sector. Financials are pretty efficient, but I would say, but even still, financials, you know, these are all, you know, managed care networks, which are very cost intensive, very heavy, you know, you know, workforce intensive.
27:09And the companies that do this right are, they're going to unlock a lot of operating leverage. And those are cash flows I want to buy. So I don't think there's any one sector, one company. Is the president right, though? If that war had continued, would there be an economic catastrophe for the United States? Yeah, I think there would have been a significant slowdown. I mean, ultimately, the inventories and the oil supply shortages would have caught up. And everybody's pretty well versed on the numbers. But is the challenge now that he said that out loud, Iran knows they have that leverage? I don't think it's news to them.
27:45I mean, I think they're following the same flow of information that the rest of us are and calculating the amount of barrels of oil that the world needs and things like that. And it was creating some real, you know, shortages and some pressures. And I also think, though, that what Iran also knew is that the world and, you know, China's a big consumer of oil, for example, would have some patience up to a certain point. And then they would start to, Iran would start to feel a lot of different pressure from their partners, because then it would really become, you know, a much bigger issue. But, look, I mean, you know, ultimately, I do think, though, we're at a stage where the point of this conflict, as far as it matters to the markets with oil prices, I think is largely behind us.
28:32I mean, where oil is today or in the mid-70s, whether you're looking at WTI or Brent, which is around 77 at the moment, this is way below what I thought it was going to be. I would have said mid-80s. I wouldn't have guessed in the 70s. So I think there's a lot to this. Our thanks to Jim Caron, Chief Investment Officer of Portfolio Solutions at Morgan Stanley Investment Management. Be sure to check out our podcast feed. More of our conversation with Jim Caron we got into positioning when it comes to global equities. Still ahead on Bloomberg Business Week, from anti-aging to muscle growth to improving anxiety and accelerating recovery from injuries, also getting a tan.
29:10There's probably a peptide for that. Or at least a peptide that says it's for that. Yeah, that's true. The explosive demand for physical optimization has minted a new underground economy. We go inside the billion-dollar peptide gold rush next. This is Bloomberg.
29:27Support for the show comes from Public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve the workflow and your agent handles the rest. Monitoring the market, watching for your conditions, and executing your strategies exactly as defined.
30:06An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., Member FINRA, and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. When you own your own business, you own every decision. Now own the card that rewards you for it. The Chase Sapphire Reserve for Business card brings the best Sapphire Reserve benefits to business owners who expect hardworking rewards.
30:49Designed to meet the needs of business owners at scale, this pay-in-full card elevates your travel experience and offers premium benefits and value toward business services that will take your business to the next level. Fuel your business and maximize rewards with 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, annual partnership credits, and more. Make every journey more rewarding with a$300 annual travel credit and access to a network of airport lounges. whether you're looking for pre-flight productivity or time to rest and recharge.
31:24Chase Sapphire Reserve for Business. It's the card that gives back all you put in. Learn more at chase.com forward slash reserve business. Chase for Business. Make more of what's yours. Accounts subject to credit approval. Restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank N.A., member FDIC. As industries evolve faster than ever, companies need an environment that accelerates strategic growth, And Michigan delivers on that promise. From emerging startups to global enterprises, Michigan offers what executives value most, a resilient, innovative ecosystem, diverse communities that attract top talent, and a quality of life that supports work-life balance.
32:02With our unified Team Michigan approach, businesses scale faster and compete at the highest level. Michigan, pure opportunity. Seize your opportunity at michiganbusiness.org. This is Bloomberg Business Week Daily with Carol Masser and Tim Stenevek on Bloomberg Radio. This is about the million-dollar peptides gold rush, and as I was reading it, I thought about a friend of mine who recently shared that he is the father of a teenage boy or two. He found some peptides in the refrigerator in the basement. Well, safe storage at least. Safe storage, but not necessarily safe injection. Yes. or safe part of the world or place that these came from.
32:49And that's really at the heart of the story. Tim, that story was written by Amanda Mull. She is Bloomberg Businessweek senior reporter and Madison Muller. She is Bloomberg News U.S. healthcare reporter. And you can, of course, check it out in its entirety. Find it on the Bloomberg Terminal and at Bloomberg.com. First of all, if people aren't familiar with peptides, Madison, start us out. What are they? Ooh, that's a good question. One of the things is that most people actually don't know what they are, don't know how to explain them, even if they think that they do. And a lot of people are injecting these things, don't really know what they are.
33:21But peptides are essentially, I mean, if you think about it, insulin's a peptide, GLP-1's are a peptide. There are a lot of legal drugs out there that are peptides, common drugs. But when we're talking about peptides, so putting it in this sort of context, we're talking about black market peptides. the ones that are not approved drugs that don't really have the rigorous safety. These were the ones in the fridge of the teenage boy. Yes. Okay, this doesn't sound good. What exactly are black market peptides? Amanda? Well, they start off as little glass vials of powder that are imported from overseas, usually from Chinese manufacturers, which, it should be noted, also produce a lot of the active pharmaceutical ingredients and perfectly legal, perfectly safe drugs.
34:08They're imported from overseas, little glass vials of powder. They're reconstituted with a special type of sterile liquid so that they can then be drawn up into a syringe and injected. And so once they're reconstituted, they have to be kept cold in order to be kept safe. So that's why they're in the fridge. Why do people want them? A whole host of reasons. For everything. For everything, basically. To sleep, to tan. One thing that may inform the question is Carol's not on Instagram. Maybe she doesn't see the same things I do. What is going on? Well, people are looking for a magic pill. As always, from the beginning of humanity, people have been looking for substances that can solve various problems.
34:57People are hopeful because GLP-1 drugs are so effective at helping people lose weight. And work. They work. They work. They're safe. They're effective. They've been used in large patient populations. So once those got popular, people started looking for other peptides to do other things in their bodies. Well, Madison, you cover the regulate, mostly the regulated pharmaceutical industry as a health care reporter. Do the black market peptides work? Does the stuff that is sold as part of, I don't know, a filler treatment at a med spa in Brooklyn or the stuff that a celebrity talks about as a secret to looking numb?
35:35It seems to know a lot about this, doesn't it? It's all in the story. I know, I know. I'm just kidding. Just kidding. Do they work? Like, is there the evidence to back it up? That is the key question. Because the thing is, like, if you ask someone, and we ask many people in the course of reporting this story, several of whom are in the story, they do work. They're life changing, but the evidence and the safety data and the effectiveness data is not there to back it up. So it's hard to know and it's hard to tease out. I mean, one of the people that we talk to in the story is on terzepatide, which is the active ingredient in Lily's drugs.
36:10They're also on multiple other things. And so it's hard to know whether the effects that they're experiencing, the anti-inflammatory effects, the weight loss, all of the things are because of Lily's drug, which we know does work. or the other things that they're on. And sometimes when people start taking these peptides, they might also start working out more or start eating healthier or doing other things. And it's just a bit hard to know what's actually happening. So the FDA is all over this, right? Well, all over it is generous. There was a little sarcasm there. Yeah, I mean, they're all over it in certain ways.
36:47Well, tell us, where are they on this? Because it's obviously people are interested, people are consuming them, right? And so where are they? Yeah, well, I think perhaps we haven't said this yet, but these drugs are like illegal to sell illegal to prescribe they are black market substances They are not approved for legal sale in the United States And the ones that are approved for legal sale if you're getting them in vials of powder You're getting an illegal version of them. That's being sold outside of patent So won't be the first time that somebody consumes an illegal substance, right? Yeah Illegal drugs are something you have a long and storied history in this country Okay, but what's worrisome though, right?
37:22And where is the government on this? Right, so RFK Jr. has said he's a peptide fan, first and foremost, and has said that because there is this overwhelming... Yeah, I know. Hold on, but that's such a... Hold on, hold on. I just want to stop you there because that's contradictory in some way because a lot of his supporters, Madison, you've been on our program talking about this. A lot of the Make America Healthy Again people are sort of anti-GLP1, which you helpfully shared with us at the beginning, is a peptide. So is there some sort of contradiction there? They're being sort of caught in a bit of a corner that they've backed themselves into, I would say.
37:55Because there is, you know, the way I would think about it is that, like, it's not an incoherent position toward science or scientific proof or towards these drugs, but it's a coherent position in regards to, like, an attitude toward authority. So getting these things outside of normal medical guidelines, outside of normal chains of expertise, outside of a doctor's office in most cases, is like a really an effective pitch for the Maha crowd for a lot of different things because it enables a person to feel like they are taking control of their health and, you know, not listening to what the government or big pharma says.
38:33So the existence of these peptide supply chains, like outside of regulatory control, is like very enticing to the whole like Maha mindset, I would say. So RFK Jr. has said that he is a fan of peptides and he has instructed the FDA's regulatory committee on compounded pharmaceuticals to look into allowing some of these drugs to be made by compounding pharmacies, which wouldn't approve them for like regular pharmacy sale in like your local CVS, but it would make them available through like sterile facilities in the U.S. Well, isn't that going to tick off Peter Magic? Or it will be more business.
39:13Or what? Yeah. Tell us about him, because that's kind of the character that kicks off your story. Do you want to go into it? Sure. He drives a fast car. Yes, that's all you need to know. Peter Magic is a chemist with a lab outside of Prague. Is Magic his real name? Yes, as far as we can tell. He owns a testing lab outside of Prague that has sort of become like a central node in the trade of black market peptides across the world. Because he started his business to test black market anabolic steroids. And peptides first gained like sort of a foothold through some of the same users like fitness, hobbyists, biohackers, people who are interested in perfecting their own form.
39:55So he realized there was an opportunity to purity and sterility test these substances because, like users of anabolic steroids, people want them, and they want them outside of legal means, but they still don't want to die because they injected something. So, Madison, does that mean they're safe? Still not necessarily. I mean, the thing that he can test these substances, he can say that they are what they purport to be, but a lot of these people like the practices of injecting yourself with a medication like some people aren't changing the syringe or they're not you know cleaning properly and like there can still be things in these drugs that are not necessarily safe and like the practice of how people are actually taking and consuming these medicines like there's just no oversight so any number of things can happen and that's sort of the problem I mean there can be medication interactions.
40:50You can be, one of the things is with some of these peptides, you need to take blood tests. You need to cycle on and off of them. So you're not essentially like poisoning yourself and not everyone knows that. So it's like all of these things that in, you know, with normal drugs and in a normal setting would have some type of doctor involved or some type of oversight or just not happening. What does the medical community say? What do doctors say? Well, we, there are some doctors who are also fans of them. And like we talked to some of them in this story and, and And those doctors are more comfortable, I would say, with the risks or aware of the risks.
41:24But they think that some of the benefits might outweigh the risks. And so it's definitely challenging. Amanda, do we get to a point where in a couple of years, this is just going to look so quaint because these have made their way through a formal approval process and will be able to buy legitimate peptides at CVS? Probably not. The FDA's process for approving drugs like this for regular commercial sale is pretty specific in the kinds of proof that it requires. And in order to, this is the same reason why it's been, until last week, it was years and years since we had gotten a new sunscreen filter approved, even though there's lots of effective ones being used in Europe and Asia for decades.
42:10The FDA requires somebody to invest in a lot of very expensive, lengthy clinical trials, in order to create the sort of safety and efficacy data that it requires in order for these drugs to be sold commercially. So because these drugs exist outside of like the normal patent process that would normally allow a single company to profit off of them exclusively for a period of time after their approval, nobody, no single company is really incentivized to go through the effort of getting these drugs, you know, tested and approved in the way that they normally would be because once they're approved, then all of their competitors can make them and sell them as well.
42:48So the FDA, at least under RFK, seems intent on, you know, sort of making an end run around that type of legalization. Or at least that's the issue that they're going to take up in a few weeks. We only have about 50 seconds left here. I'm just like, in reporting this out, because there are people, as you say, it's all over social and people are looking at this and thinking, should I take this? What's a quick thought to them, Madison, or what did you learn in kind of doing this? I mean, I think that it will be really important for people to tune into this FDA meeting that's happening in July, where they will literally be reviewing the evidence and the data around these things.
43:28There are independent experts on this committee that will be talking about that. And most of the people that we talk to say there really isn't any evidence or human data on this. So I think like, hopefully that will make people aware of the situation more. 15 seconds for you, Amanda. Well, I think many of their proponents agree that there's not any data, but they think that they should be able to give it a shot if they want to. Our thanks to Amanda Moll, Bloomberg Businessweek senior reporter, and Madison Muller, Bloomberg News U.S. healthcare reporter. Check out their story in Bloomberg Businessweek.
43:58It's a great read. Check it out. It's also online. And that wraps up the weekend edition of Bloomberg Business Week from Bloomberg Radio. Thank you so much for joining us. Be sure to tune into Bloomberg Business Week daily, Monday through Friday, starting at 2 p.m. Wall Street time on Bloomberg Radio, Bloomberg TV, and on Sirius XM channel 121. Also, just a shout out to Sebastian Escobar for hooking us up each and every week with his weekend programming. Aw, that's really kind. I mean, he does a lot. I know, he does kind of everything. Travels on the road with us. Well, he puts up with us. And that's a big part of it.
44:29Hey, you can also watch our daily broadcast on YouTube. Just search Bloomberg Podcasts. We're simulcast on Bloomberg Originals, available on Bloomberg.com slash originals and streaming platforms, including Roku, Amazon Fire TV, Samsung TV Plus, and more. Find our Bloomberg Business Week podcast at Bloomberg.com, Apple, or wherever you get your podcasts. And the latest edition of the magazine, it's available on newsstands now at Bloomberg.com and always on the Bloomberg Terminal. I'm Tim Stenevich. And I'm Carol Master. Have a good and safe weekend, everyone. Stay with us. Today's top stories and global business headlines are coming up right now.
45:02When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges. At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience. Learn more at thehartford.com slash risk mitigation.
45:37Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. This dog salon? Operational excellence. Thanks to genius from Global Payments. Scheduling? Personalized. Checkouts? Instant. Absolutely genius. Big League reliability for any business. That's genius. Never bet against American grit or American energy. Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time. So while others are busy talking, we're busy building.
46:20That's Venture Global. That's unstoppable energy.
From the publisher
Featuring some of our favorite conversations of the week from our daily radio show “Bloomberg Businessweek Daily.”
Hosted by Carol Massar and Tim Stenovec
Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius/XM channel 121, on the Bloomberg Business App, Radio.com, the iHeartRadio app and at Bloomberg.com/audio.
You can also watch Bloomberg Businessweek Daily on YouTube - just search for Bloomberg Global News.
Like us at Bloomberg Radio on Facebook and follow us on Twitter @carolmassar @timsteno and @BW
See omnystudio.com/listener for privacy information.
